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ABSTRACT
Original Article
Background and Objectives
In follicular lymphoma histological grading is used to predict clinical behavior and to
stratify patients for treatment. However, the reproducibility of histological grading is
poor and the clinical significance of the difference between grade 1 and grade 2 fol-
licular lymphoma is unclear. Data on proliferation characteristics with respect to prog-
nosis in follicular lymphoma are inconsistent.
Design and Methods
We assessed the Proliferation Index in follicles, using Mib-1 immunohistochemical
staining in lymph node biopsies from 51 patients with follicular lymphoma who were
receiving uniform first-line treatment consisting of cyclophosphamide, vincristine,
prednisone and interferon α2b.
Results
The median Proliferation Index was 16.9 (range 3.1-49.2). In grades 1 and 2 follicu-
lar lymphoma (n=45) it was 16.1, compared to 24.2 in grade 3 (n=6; p=0.02). At a
median follow-up of 71 months, patients with a Proliferation Index below the median
had a significantly prolonged time to progression (median not reached vs. 15 months
for those with a Proliferation Index above the median; p=0.0006) and improved over-
all survival (median not reached vs. 42 months, respectively; p=0.002). In multivari-
ate analysis, the Proliferation Index retained its predictive value. Additional prognos-
tic information was especially provided in patients with a low International Prognostic
Index. Histological grade did not predict outcome.
Interpretation and Conclusions
The Proliferation Index is a biological marker that is strongly and independently pre-
dictive for outcome in follicular lymphoma, as shown even in this relatively small
series of patients. It is easily applicable and reproducible and therefore superior to
histological grading in identifying clinically aggressive follicular lymphoma, requiring
other types of treatment.
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Proliferation in follicular lymphoma
Follicular lymphoma is the second most commonlymphoma and is usually characterized by an indo-lent course. Most patients present with advanced
stage disease and at some point require therapy, which
typically results in only a temporary remission. Follicular
lymphoma is currently treated with chemotherapy, radio-
therapy, interferon α and several forms of specific
immunotherapy (using anti-CD 20 monoclonal antibod-
ies), but no curative treatment, with the possible excep-
tion of allogeneic stem cell transplantation, is available.
One of the main issues in follicular lymphoma is to
identify patients with an adverse prognosis who might
benefit from more intensive treatment or experimental
treatment modalities. Apart from clinical prognostic
indices such as the International Prognostic Index and the
Follicular Lymphoma International Prognostic Index,1-3
stratification for treatment is often based on histological
grading.4,5 Given identical treatment, patients with grade
3 follicular lymphoma have a worse prognosis than those
with grade 1 or 2 follicular lymphoma, but when treat-
ment is intensified by anthracycline-containing regimens,
this difference disappears.6-8 A major problem in histolog-
ical grading is the considerable intra- and inter-observer
variability,9,10 due to the subjective nature of the tech-
nique. Although the fraction of proliferating cells is prog-
nostic in aggressive lymphomas,11,12 its predictive value in
follicular lymphoma is less clear. It is difficult to interpret
data from studies on proliferation in follicular lymphoma
because of differences in methodology and patient popu-
lations. To evaluate the prognostic significance of the pro-
liferation rate in indolent follicular lymphoma, we studied
the intra-follicular Proliferation Index in relation to histo-
logical grade and clinical outcome in 51 patients with
indolent follicular lymphoma. 
Design and Methods
Patients
Consecutive patients with previously untreated indo-
lent follicular non-Hodgkin’s lymphoma in Ann Arbor
stages II bulky (larger than 5 cm), III or IV who started
treatment between December 1994 and January 2000
were included in this study. All patients were uniformly
treated according to local guidelines with eight 4-weekly
CVP courses [cyclophosphamide 750 mg/m2 intravenous-
ly on day 1, vincristine 1.4 mg/m2 (to a maximum of 2
mg)] intravenously on day 1, and prednisone 60 mg/d
orally on days 1-5) in combination with interferon α2b
(5×106 IU subcutaneously 3 times a week) as induction
therapy. Thereafter, responding patients received mainte-
nance treatment with interferon α2b (5×106 IU subcuta-
neously 3 times a week) until intolerable toxicity, relapse
or progressive disease, whichever came first.13 An initial
wait-and-see period was allowed before induction thera-
py was started. When relapse or progressive disease
occurred, further treatment was left to the discretion of
the treating physician. Staging was done according to the
Ann Arbor criteria, by a thorough physical examination,
computed tomography scanning of the thorax and
abdomen and unilateral trephine bone marrow biopsy. 
At the time of patient accrual, the Follicular Lymphoma
International Prognostic Index had not been introduced
and the exact number of involved nodal areas – one of the
five components of this Index – was not documented.
Therefore, for the purpose of this study the International
Prognostic Index was used rather than the Follicular
Lymphoma International Prognostic Index. The clinical
data of the patients were collected prospectively. All
patients visited the outpatient clinic at each cycle of che -
mo therapy and every 3 months during interferon mainte-
nance therapy and follow-up.
Histological grading
All lymphoma specimens were centrally reviewed by
two experienced hemato-pathologists (JHJMvK and KH)
and were classified and graded according to the WHO
criteria.14 The absolute number of centroblasts in ten
neoplastic follicles was counted using a 40x high-power
microscopic field (hpf, 0.159 mm2). Grade 1 cases had 0-
5 centroblasts/hpf, grade 2 cases had 6-15 centro -
blasts/hpf and grade 3 cases had >15 centroblasts/hpf.
In grade 3a follicular lymphoma centrocytes were still
present whereas grade 3b was defined as follicles con-
sisting of solid sheets of centroblasts only.
Immunohistochemistry 
The fraction of proliferating cells (Proliferation Index)
was assessed in samples of lymph node biopsies taken
at the time of diagnosis of the lymphoma. The samples
had been fixed in formalin and embedded in paraffin
using routine methods. First, we identified the nature of
proliferating cells by both CD20/mib-1 and CD3/mib-1
immunohistochemical double staining, thus visualizing
proliferating B-cells and non-tumor T cells. Staining was
performed by routine techniques; visualization was
done with di-amino benzidine (DAB) for the anti-CD3
and the anti-CD20 antibody and with Fast Red for the
mib-1 antibody. For the quantification of the
Proliferation Index only the mib-1 antibody (a mono-
clonal mouse anti-human antibody directed against the
Ki-67 antigen) (DAKO, Denmark) was used as a prolif-
eration marker. For this quantification, 5µm thick paraf-
fin sections were mounted onto 3-amino-propyltri-
ethoxysilane (APS)-coated slides. After deparaffination,
inhibition of endogenous peroxidase and microwave
cooking in citrate buffer for 10 minutes, the sections
were incubated for 1 hour at room temperature with the
mib-1 antibody. Subsequently, after washing with phos-
phate-buffered saline, the sections were incubated with
biotinylated horse anti-mouse and peroxidase-conjugat-
ed avidin. Visualization was performed with DAB sub-
strate and counterstaining with methylene blue. 
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Intra- and extra-follicular proliferation
In general, the number of proliferating cells was
greater in the follicles than in inter-follicular areas
(Figure 1A). There were few intra-follicular T-cells
(Figure 1B), whereas there were abundant inter-follicu-
lar T cells, including mib-1 positive T cells (Figure 1C-
D). Thus, it essential to realize that inter-follicular pro-
liferating cells do not solely represent tumor cells and
should not be included in the Proliferation Index of the
tumor B cells. Therefore, the Proliferation Index was
analyzed on intra-follicular cells.
Assessment of the proliferation Index
In each section 200 cells per follicle were assessed in
five randomly selected follicles using a 40x hpf, for a
total of 1000 cells per section. A cell was considered
mib-1 positive when any amount of brown staining was
present, regardless of the intensity of the staining. The
Proliferation Index was defined as (no. of mib-1 positive
cells/ total no. of cells) x 100. All sections were assessed
by one investigator (HAT), blinded to the clinical data of
the patients. To establish inter-observer variability, a
control series of 25 randomly selected sections (50%)
was assessed by a second investigator (AK) blinded to
the outcome of the first assessment and the clinical data
of the patients.
Statistical analysis
The inter-observer variability was evaluated by calcu-
lating the coefficient of variation and Spearman’s rank
correlation. Differences between groups were analyzed
using the Mann-Whitney U test or the Kruskal-Wallis
test. Progression-free survival (PFS) and overall survival
(OS) were measured from the start of induction therapy
with CVP and interferon-α until the time of disease pro-
gression or death from any cause, respectively, or until
the end of the observation period. In patients whose
management included an initial wait-and-see policy, PFS
and OS were also measured from the date the induction
therapy was started. Survival curves were calculated
according to the Kaplan-Meier method and  the Cox
proportional hazards model was used for the analysis.
The level of statistical significance was set at 0.05 (two-
sided). 
Results
Patients
Between December 1994 and January 2000, 62 con-
secutive patients with follicular lymphoma started treat-
ment according to the guidelines. Adequate biopsy
material to perform immunohistochemical staining was
available from 51. The clinical characteristics of these
patients are summarized in Table 1. In eight patients an
initial wait-and-see policy was adopted, which lasted a
median of 11 months (range, 2-32 months). During the
follow-up, which lasted a median of 71 months, 21
patients (41%) died: three patients in the group who
achieved a complete remission after induction therapy,
11 in the group who had a partial remission and seven
in the group with progressive disease. Sixteen patients
did not receive all eight CVP courses, eight of whom
because of progressive disease during induction therapy. 
Reproducibility of the Proliferation Index
The Proliferation Index ranged from 3.1 to 49.2 with
a median of 16.9. The median value of the Proliferation
Index in the series assessed by the second investigator
was 17.6 (range 4.2-59.2). The coefficient of variation
was 0.14 and the correlation coefficient of the two
assessments was 0.81 (p<0.001). 
The Proliferation Index in clinical and histological
subgroups
The Proliferation Index in different clinical and histo-
logical subgroups is shown in Table 2. The Proliferation
Index was significantly lower in patients with histolog-
ical grade 1 or 2 lymphoma than in those with grade 3
lymphoma (Figure 2). Remarkably, the Proliferation
Index was higher in patients in whom treatment was
commenced some time after the diagnosis (i.e. follow-
ing a wait-and-see policy) than in patients who were
treated immediately at the time of diagnosis. 
The Proliferation Index and patients’ outcome
After a median follow-up of 71 months, the median
PFS for all patients was 25 months, whereas the median
OS was not reached. The median PFS and OS according
to the Proliferation Index are shown in Table 3. Both PFS
and OS were significantly shorter in patients with a
high Proliferation Index, regardless of the cut-off point.
When the six patients with grade 3 follicular lymphoma
Figure 1. Sections of lymph nodes with follicular lymphoma; intra-
and inter-follicular proliferation. (A) Mib-1 staining (brown) shown
at 100× original magnification. Note the typically increased prolif-
eration in the follicles. (B, C, D) Mib-1 (pink) and anti-CD3 staining
(brown) shown at 400× original magnification. Note the abundant
presence of T cells and double-stained proliferating T cells
(arrows) in the inter-follicular region (C, D) compared to intra-fol-
licularly (B).
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Table 1. Patients’ characteristics, histological grade, response to
induction therapy and interferon use.
All patients 
n=51
Age (years)
Median 53.3
Sex
Male 30
Female 21
Ann Arbor stage
II 3
III 11
IV 37
Bone marrow involvement
Present 35
Absent 13
Bulky disease (more than 5 cm)
Present 20
Absent 29
WHO performance
Not more than 1 42
More than 1 7
B-symptoms
Present 9
Absent 41
Lactate dehydrogenase
Normal 37
Above normal 11
Extranodal localization apart from bone marrow
Present 3
Absent 46
International Prognostic Score
0 3
1 24
2 17
3 3
4 1
Berard grade
1 35
2 10
3 6
Response to induction  therapy
Complete remission 18
Partial remission 23
Stable disease 1
Progressive disease 9
Interferon stopped due to toxicity 14
were excluded from the analysis, the results remained
significant. Importantly, the Proliferation Index also
maintained its prognostic impact on PFS and OS when
tested as a continuous variable. PFS and OS in patients
with the Proliferation Index above and below the medi-
an are shown in Figure 3.
Other parameters that were associated with a worse
OS in univariate analysis were male sex, the presence of
bulky disease and an intermediate or high International
Prognostic Index. When these parameters were tested in
multivariate analysis the association of high Prolifer -
ation Index with a worse OS retained its significance
(Table 4). In the subgroup of patients with a favorable
clinical profile as indicated by a low International
Prognostic Index, both PFS and OS were significantly
worse in patients with a Proliferation Index above the
median (n=17) than in those with a low Proliferation
Index (n=12) (Figure 4A). This difference was absent in
patients with an intermediate or high International
Prognostic Index (Figure 4B), although the number of
patients was too low to draw any firm conclusions for
this subset of patients. 
Histological grade did not significantly predict PFS or
OS (p>0.4 for OS), probably due to the low number of
grade 3 cases. 
Discussion
Follicular lymphoma is a clinically heterogeneous dis-
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Table 2. Median Proliferation Index (PI) in clinical and histological
subgroups.
n Median PI p value
Bulky disease present 19 18.2 NS
Bulky disease absent 29 16.4
Histological transformation 8 16.9 NS
No transformation 43 18.3
Wait-and-see policy 8 22 0.03
No wait-and-see policy 43 15
Complete remission° 18 12.4 0.055
Partial remission° 23 19.4
Progressive disease° 9 21.7
Histological grade 1 35 16.4 0.02*
Histological grade 2 10 12.6
Histological grade 3 6 24.2
°After induction therapy; NS: not statistically significant. *p-value when grades 1
and 2 combined are compared to grade 3. The total in the different characteristics
can be less than 51 due to missing data.
Table 3. Progression-free survival and overall survival according to
the Proliferation Index and histological grade.
n Median PFS p Median OS p
(months) (months)
PI > median 25 15 0.0006 42 0.002
PI < median 26 NR NR
PI upper tertile 17 15 0.009 40 0.017
PI lower two tertiles 34 34 NR
PI upper quartile 12 14 0.026 41 0.007
PI lower three quartiles 39 30 NR
PI as a continuous variable 0.016 0.053
Histological grade 1 35 24 NS NR NS
Histological grade 2 10 30 NR
Histological grade 3 6 15 60
PI: Proliferation Index; PFS: progression-free survival; OS: overall survival;
NR: not reached; NS: not statistically significant. 
ease with considerable differences in survival times. To
improve outcome, the identification of patients at risk
of early progression and death is as important as the
development of new therapeutic modalities. We estab-
lished the prognostic value of the intra-follicular
Proliferation Index in patients with follicular lym-
phoma, treated with CVP chemotherapy plus interfer-
on-α. The Proliferation Index is significantly associated
with both PFS and OS, independently of other risk fac-
tors, including the clinically-based International
Prognostic Index score. In contrast to the International
Prognostic Index, the Proliferation Index is of predictive
value for PFS and response rate to induction therapy.
Importantly, we demonstrate that within the large
group of patients who belong to the low-risk group
according to the International Prognostic Index, the pro-
liferation characteristic significantly identifies patients
with a very poor prognosis. 
In this study, as in most studies on the significance of
proliferation in follicular lymphoma,15-21 there was an
association between large cell histology and a higher
proliferative activity. However, a large overlap was pres-
ent indicating an inherent difference between large cell
morphology and proliferation characteristics. A major
concern about histological grading is its lack of repro-
ducibility,9,10 which precludes its general application. In
contrast, the reproducibility of the Proliferation Index
was excellent. There was no statistically significant cor-
relation between PFS or OS and histological grade,
mainly due to the small number of patients with grade
3 follicular lymphoma. The median Proliferation Index
of the patients in whom a wait-and-see policy was
adopted was higher than that in those who were treat-
ed immediately after diagnosis. This may seem to be in
contradiction with the observed prognostic value of the
Proliferation Index. It should, however, be noted that
eventually all patients received treatment. Apparently,
the prognostic information of the Proliferation Index is
valid in chemotherapy-treated patients; it may be less
suitable for selecting those patients in whom starting
therapy can be delayed. Prospective studies in which
patients are stratified according to the Proliferation
Index are needed to elucidate this aspect further.
Few studies have addressed proliferation in relation to
outcome in follicular lymphoma. Cibull et al.15 investigat-
ed lymph node biopsies from 33 patients with follicular
lymphoma by performing Ki-67 immunostaining and sil-
ver nuclear organizer region counting (AgNOR). The pro-
liferation rate did not predict survival. Llanos et al.16 stud-
ied 49 patients with follicular lymphoma and used a semi-
quantitative grading system to quantify Ki-67 positivity in
areas of highest Ki-67 expression. No correlation was
found between Ki-67 expression and OS. Czader et al.22
manually quantified the mib-1 positive fraction in the fol-
licles of lymph node sections from 49 patients with follic-
ular lymphoma. Although the range of the Proliferation
Index in this study was identical to that in our study, they
found that achievement of a complete remission was
associated with a high proliferation fraction. The prolifer-
ation rate did not correlate with survival times. A large
study on proliferation in follicular lymphoma was con-
ducted by Martin et al.,17 who examined 106 cases. They
reported a positive correlation between the Proliferation
Index and OS, but this failed to be statistically significant
when tested in multivariate analysis together with the
histological grade, age and the International Prognostic
Index. As in our study, the proliferative rate was correlat-
ed with the histological grade of follicular lymphoma.
Importantly, 60% of the patients in Martin’s study were
classified as having follicular large cell lymphoma (i.e.
grade 3 follicular lymphoma). Of the remaining 40% only
five patients (4.7%) had follicular small cell lymphoma
(grade 1 follicular lymphoma). In our study only 12% of
the cases were classified as having grade 3 follicular lym-
phoma whereas 69% had grade 1 disease. Our study
should, therefore, be considered as a study addressing
really indolent follicular lymphoma, whereas Martin’s
Figure 2. Proliferation indices of grades 1 and 2 FL combined,
compared to grade 3 FL. The median value is indicated.
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Table 4. Factors prognostic for overall survival.
Variable Hazard ratio (95%-confidence interval)
n univariate multivariate
Male vs. female 29/21 2.31 (0.90-5.97) 1.56 (0.56-4.32)
Bulky disease: 19/29 3.39 (1.39-8.30)* 2.76 (0.99-7.69)
present vs. absent
Proliferation Index 25/26 3.88 (1.49-10.10)* 2.92 (1.08-7.94)*
above vs. below 
the median
IPI not low vs. low 20/29 4.05 (1.64-9.98)* 4.31 (1.65-11.25)*
The total in the different characteristics can be less than 51 due to missing data.
*statistically significant (p<0.05).
study focused on more aggressive variants of follicular
lymphoma. In addition, all patients in the study by Martin
et al, including those with grade 1 or 2 follicular lym-
phoma, received anthracycline-containing chemo ther -
apeutic regimens as primary treatment, whereas none of
our patients was treated anthracyclines. A third point of
difference concerns the methodology of assessing prolifer-
ation. Martin et al. used a quantitative image analysis sys-
tem, whereas we chose to measure the Proliferation Index
manually. Manual counting avoids over-estimation of the
number of centroblasts, which are larger. In addition,
measurement fields in the study by Martin et al. were not
randomly chosen, thereby introducing a bias in the analy-
sis that may have affected reproducibility.
Recently, in patients with low grade follicular lym-
phoma Wang et al. failed to show a significant difference
in OS between those with a high Proliferation Index and
those with a low Index.23 The shape of the survival
curve of patients with low grade follicular lymphoma
with a high Proliferation Index was remarkably similar
to that of patients with grade 3 follicular lymphoma.
Also disease-specific survival was significantly better in
patients with a low Proliferation Index, corroborating
our observations. This study was, however, retrospec-
tive and patients were not treated uniformly. Moreover,
the fraction of proliferating cells was estimated and not
actually counted and no multivariate analysis with other
predictors of outcome was performed.
The combination of CVP chemotherapy plus the
monoclonal anti-CD20 antibody rituximab has been
demonstrated to be superior to CVP alone and is now
considered the new standard treatment for follicular
lymphoma.24 In a small series of patients with follicular
lymphoma treated with rituximab plus chemotherapy, a
significant correlation was found between inferior treat-
ment response and high mib-1 expression.25 This corrob-
orates our observations, and indicates that proliferative
rate may maintain its value as a prognosticator in the rit-
uximab era. Nevertheless, the prognostic significance of
the intra-follicular Proliferation Index should be validat-
ed in a prospectively followed cohort of patients treated
with a rituximab-containing regimen.
In conclusion, we observed that the intra-follicular
Proliferation Index is a strong and independent prognos-
tic factor for PFS and OS in follicular lymphoma, while
histological grading did not predict patients’ outcome in
our series of patients. Additional prognostic information
is especially provided in patients classified as having a
low risk of early progression according to accepted clin-
ical parameters, even given the relatively small number
of patients studied. Manual assessment of the
Proliferation Index is easily applicable and reproducible
and can serve as a method for stratifying patients in clin-
ical trials to select patients needing more intensive treat-
ment and to discriminate them from patients with an
upfront good prognosis who might be over-treated with
an intensive first-line approach.
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Figure 3. Progression-free survival (A) and overall survival (B) of
patients with a Proliferation Index (PI) above or below the medi-
an.
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